医学
左旋西孟旦
心脏病学
肺楔压
内科学
心力衰竭
肺动脉高压
射血分数
血流动力学
射血分数保留的心力衰竭
作者
Michael I. Brener,Nadira Hamid,Kenji Sunagawa,Barry A. Borlaug,Sanjiv J. Shah,Stuart Rich,Daniel Burkhoff
标识
DOI:10.1016/j.cardfail.2021.05.022
摘要
Levosimendan is a K+-ATPase activator, cardiac myofilament Ca2+sensitizer, and phosphodiesterase inhibitor with positive inotropic effects and vasodilatory properties in the pulmonary and systemic circulation, all of which are potential therapeutic targets for patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). 1 Gorter TM Obokata M Reddy YNV Melenovsky V Borlaug BA. Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J. 2018; 39: 2825-2835 Crossref PubMed Scopus (88) Google Scholar In the recent multicenter, double-blind, placebo-controlled Hemodynamic Evaluation of Levosimendan in Patients with HFpEF (HELP) study, a weekly infusion of levosimendan decreased the pulmonary capillary wedge pressure (PCWP) and central venous pressure, and was associated with a significant increase in 6-minute walk distance. 2 Burkhoff D Borlaug BA Shah SJ Zolty R Tedford RJ Thenappan T et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail. 2021; 9: 360-370 Crossref PubMed Scopus (10) Google Scholar However, the mechanism(s) underlying levosimendan's effects were not elucidated fully. The purpose of this report is to integrate hemodynamic and echocardiographic data from the HELP study to determine which cardiovascular effects of levosimendan contributed to the finding of decreased right and left heart filling pressure in PH-HFpEF.
科研通智能强力驱动
Strongly Powered by AbleSci AI